Axogen, Inc. Hits New 52-Week High of $22.95, Surges 217.86%

Axogen, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 22.95 on October 29, 2025. This achievement marks a remarkable increase from its 52-week low of USD 9.22, showcasing a substantial year-over-year performance of 217.86%. In comparison, the S&P 500 has seen a more modest gain of 18.33% during the same period.
With a market capitalization of USD 738 million, Axogen operates within a competitive industry landscape. The company currently has a debt-to-equity ratio of 0.13, indicating a relatively low level of debt compared to its equity. However, it is important to note that Axogen is currently not generating profits, as reflected by its loss-making status and a return on equity of -4.49%. The stock does not offer a dividend yield, aligning with its growth-focused strategy. As Axogen continues to navigate the dynamic biotechnology market, its recent price performance underscores its evolving position within the industry.